Biophytis SA announced the filing of a patent application in the treatment of obesity, a new indication in which the Company has positioned itself with the announcement of its phase 2 OBA clinical trial. This new patent application, which is expected to be granted as soon as 2025, will strengthen BIO101's (20-hydroxyecdysone) position in the treatment of obesity in combination with GLP-1 RAs. This new patent will extend the exclusivity period of BIO101 (20-hydroxy) in this indication until 2044.

With promising results in obesity from preclinical studies and in the SARA-INT phase 2 study, BIO101 (20- hydroxyecdysone) has demonstrated its potential to become the molecule of choice for preserving muscle function in patients suffering from obesity treated with GLP-1 R As. Subject to regulatory approvals, the drug candidate could help address a critical medical problem, while positioning Biophytis in a large and fast-growing market.